Lymphangiogenesis in aortic valve stenosis-Novel regulatory roles for valvular myofibroblasts and mast cells

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 366-374

  Syväranta, Suvi ^a   Helske, Satu ^a,b   Lappalainen, Jani ^a   Kupari, Markku ^b   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Aortic valve stenosis; Lymphangiogenesis; Mast cells; Myofibroblasts; Vascular endothelial growth factor C

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AORTA VALVE; AORTA VALVE STENOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHANGIOGENESIS; MAST CELL; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION;

AORTIC VALVE; AORTIC VALVE STENOSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MAST CELLS; MYOFIBROBLASTS; PEPTIDE HYDROLASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VESICULAR TRANSPORT PROTEINS;

EID: 84858703912     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.034     Document Type: Article

References (35)

1. Helske S., Otto C.M. Lipid lowering in aortic stenosis: still some light at the end of the tunnel. Circulation 2009, 119:2653-2655.
2. Mohler E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
3. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
4. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004, 36:57-66.
5. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
6. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
7. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004, 44:1859-1866.
8. Olsson M., Dalsgaard C.J., Haegerstrand A., et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994, 23:1162-1170.
9. Soini Y., Salo T., Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 2003, 34:756-763.
10. Helske S., Kupari M., Lindstedt K.A., et al. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007, 18:483-491.
11. Syvaranta S., Helske S., Laine M., et al. Vascular endothelial growth factor-secreting mast cells and myofibroblasts: a novel self-perpetuating angiogenic pathway in aortic valve stenosis. Arterioscler Thromb Vasc Biol 2010, 30:1220-1227.
12. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227.
13. Bradham R.R., Parker E.F., Barrington B.A., et al. The cardiac lymphatics. Ann Surg 1970, 171:899-902.
14. Kholova I., Dragneva G., Cermakova P., et al. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 2010, 41:487-497.
15. Steiner I., Krbal L., Dominik J. Blood vessels and lymphatics in calcific aortic stenosis - in support of its inflammatory pathogenesis. Cesk Patol 2010, 46:33-36.
16. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15:290-298.
17. Yamada Y., Nezu J., Shimane M., et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997, 42:483-488.
18. Achen M.G., Jeltsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998, 95:548-553.
19. Cueni L.N., Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol 2006, 126:2167-2177.
20. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005, 5:735-743.
21. Cao R., Bjorndahl M.A., Gallego M.I., et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006, 107:3531-3536.
22. Lohela M., Bry M., Tammela T., et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21:154-165.
23. Bjorndahl M.A., Cao R., Burton J.B., et al. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 2005, 65:9261-9268.
24. Partanen T.A., Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001, 55:108-121.
25. Detoraki A., Staiano R.I., Granata F., et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol 2009, 123:1142-1149.
26. Helske S., Syvaranta S., Lindstedt K.A., et al. Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 2006, 26:1791-1798.
27. Helske S., Laine M., Kupari M., et al. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J 2007, 28:1894-1903.
28. Lappalainen J., Lindstedt K.A., Kovanen P.T. A protocol for generating high numbers of mature and functional human mast cells from peripheral blood. Clin Exp Allergy 2007, 37:1404-1414.
29. Helske S., Syvaranta S., Kupari M., et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006, 27:1495-1504.
30. Helske S., Oksjoki R., Lindstedt K.A., et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008, 196:190-200.
31. Deckers M.M., Karperien M., van der Bent C., et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000, 141:1667-1674.
32. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005, 14:80-87.
33. Enholm B., Paavonen K., Ristimaki A., et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997, 14:2475-2483.
34. Leppanen P., Koota S., Kholova I., et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005, 112:1347-1352.
35. Nakano T., Nakashima Y., Yonemitsu Y., et al. Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol 2005, 36:330-340.